Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies....more
3/31/2025
/ Biotechnology ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Health Care Providers ,
Insider Trading ,
Life Sciences ,
Medical Devices ,
Medicare ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Scienter ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Fraud ,
Securities Litigation
Delaware Court of Chancery Denies Motion to Dismiss in Shareholder Class Action Lawsuit Related to Mindbody Inc.’s Billion Dollar Merger with Vista Equity Partners; Second Circuit Unanimously Affirms Lower Court’s Decision...more
10/21/2020
/ Bad Faith ,
Breach of Duty ,
Business Judgment Rule ,
Class Action ,
Conflicts of Interest ,
Dismissal With Prejudice ,
Dismissals ,
Donald Trump ,
Duty of Care ,
Fiduciary Duty ,
Gross Negligence ,
Investors ,
Loss Causation ,
Mergers ,
Misrepresentation ,
Motion to Dismiss ,
Popular ,
Proxy Materials ,
Public Disclosure ,
Reversal ,
Securities Fraud ,
Securities Litigation ,
Shareholder Votes ,
Shareholders ,
Subpoenas ,
Tax Returns ,
Whistleblowers
Securities Class Action Against Swiss-Based Company Dismissed On Forum Non Conveniens Grounds; Second Circuit Finds Strong Inference of “Conscious Recklessness” In Allegations And Reverses Dismissal of Securities Suit Against...more
8/25/2020
/ Bribery ,
Class Action ,
Cross-Border Transactions ,
Department of Justice (DOJ) ,
Dismissals ,
False Statements ,
Foreign Corporations ,
Foreign Corrupt Practices Act (FCPA) ,
Forum Non Conveniens ,
Forum Selection ,
Government Investigations ,
Investors ,
Misleading Statements ,
Omissions ,
Pharmaceutical Industry ,
Popular ,
Putative Class Actions ,
Real Estate Investments ,
Recklessness ,
Reversal ,
Rule 10b-5 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Litigation ,
Settlement